Compound ID | 129
Class: Glycopeptide
| Spectrum of activity: | Gram-positive |
| Details of activity: | MRSA (methicillin resistant Staphylococcus aureus) and VRE (vancomycin resistant Enterococcus sp.) |
| Propensity to select resistant mutants: | Yes |
| Institute where first reported: | Cooper Group, University of Queensland, Australia |
| Year first mentioned: | unknown |
| Highest developmental phase: | Preclinical |
| Development status: | Experimental |